SG11201606624WA - Antibody moleules to dengue virus and uses thereof - Google Patents

Antibody moleules to dengue virus and uses thereof

Info

Publication number
SG11201606624WA
SG11201606624WA SG11201606624WA SG11201606624WA SG11201606624WA SG 11201606624W A SG11201606624W A SG 11201606624WA SG 11201606624W A SG11201606624W A SG 11201606624WA SG 11201606624W A SG11201606624W A SG 11201606624WA SG 11201606624W A SG11201606624W A SG 11201606624WA
Authority
SG
Singapore
Prior art keywords
moleules
antibody
dengue virus
dengue
virus
Prior art date
Application number
SG11201606624WA
Inventor
Luke Robinson
Zachary Shriver
James Myette
Gregory Babcock
Karthik Viswanathan
Original Assignee
Visterra Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Visterra Inc filed Critical Visterra Inc
Publication of SG11201606624WA publication Critical patent/SG11201606624WA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1081—Togaviridae, e.g. flavivirus, rubella virus, hog cholera virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/42—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum viral
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56983—Viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/54—F(ab')2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
    • G01N2333/08—RNA viruses
    • G01N2333/18—Togaviridae; Flaviviridae
    • G01N2333/183—Flaviviridae, e.g. pestivirus, mucosal disease virus, bovine viral diarrhoea virus, classical swine fever virus (hog cholera virus) or border disease virus
    • G01N2333/185—Flaviviruses or Group B arboviruses, e.g. yellow fever virus, japanese encephalitis, tick-borne encephalitis, dengue
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
SG11201606624WA 2014-02-11 2015-01-20 Antibody moleules to dengue virus and uses thereof SG11201606624WA (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201461938646P 2014-02-11 2014-02-11
US201462017970P 2014-06-27 2014-06-27
US201462046379P 2014-09-05 2014-09-05
PCT/US2015/011965 WO2015122995A1 (en) 2014-02-11 2015-01-20 Antibody moleules to dengue virus and uses thereof

Publications (1)

Publication Number Publication Date
SG11201606624WA true SG11201606624WA (en) 2016-09-29

Family

ID=52478058

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201606624WA SG11201606624WA (en) 2014-02-11 2015-01-20 Antibody moleules to dengue virus and uses thereof

Country Status (12)

Country Link
US (5) US9212217B2 (en)
EP (2) EP4047015A1 (en)
JP (1) JP6764348B2 (en)
KR (1) KR102356951B1 (en)
CN (2) CN113817053A (en)
AU (1) AU2015217572B2 (en)
CA (2) CA3212977A1 (en)
ES (1) ES2900749T3 (en)
IL (1) IL247221B (en)
MX (1) MX2016010360A (en)
SG (1) SG11201606624WA (en)
WO (1) WO2015122995A1 (en)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2010003450A (en) 2007-09-26 2010-04-27 Chugai Pharmaceutical Co Ltd Modified antibody constant region.
SG11201500605TA (en) 2012-08-07 2015-02-27 Massachusetts Inst Technology Anti-dengue virus antibodies and uses thereof
KR102356951B1 (en) 2014-02-11 2022-01-27 비스테라, 인크. Antibody molecules to dengue virus and uses thereof
WO2015123362A1 (en) * 2014-02-11 2015-08-20 Massachusetts Institute Of Technology Novel full spectrum anti-dengue antibody
CN114773470A (en) 2015-02-05 2022-07-22 中外制药株式会社 Antibodies comprising an ion concentration-dependent antigen-binding domain, FC region variants, IL-8-binding antibodies and uses thereof
EP3271390B1 (en) * 2015-03-17 2023-09-27 Agency For Science, Technology And Research A serotype cross-reactive, dengue neutralizing antibody and uses thereof
TW201718638A (en) 2015-07-21 2017-06-01 現代治療公司 Infectious disease vaccines
US20170274076A1 (en) * 2016-03-25 2017-09-28 Visterra, Inc. Formulations of antibody molecules to dengue virus
WO2017181098A2 (en) * 2016-04-15 2017-10-19 Visterra, Inc. Antibody molecules to zika virus and uses thereof
CN116271014A (en) 2016-08-05 2023-06-23 中外制药株式会社 Compositions for preventing or treating IL-8 related diseases
SG10201607778XA (en) 2016-09-16 2018-04-27 Chugai Pharmaceutical Co Ltd Anti-Dengue Virus Antibodies, Polypeptides Containing Variant Fc Regions, And Methods Of Use
TWI769185B (en) * 2016-10-27 2022-07-01 海樂源有限公司 Dengue virus-like particle, antibody against dengue virus, and composition comprising the same
CR20190291A (en) * 2016-12-23 2019-11-05 Serum Institute Of India Pvt Ltd Improved methods for enhancing antibody productivity in mammalian cell culture and minimizing aggregation during downstream, formulation processes and stable antibody formulations obtained thereof
US11370830B2 (en) 2017-04-07 2022-06-28 The Rockefeller University Neutralizing antibodies that bind to the zika virus domain III envelope region
EP3621645A4 (en) * 2017-05-10 2021-01-27 University of Massachusetts Bivalent dengue/hepatitis b vaccines
US11576962B2 (en) 2017-12-21 2023-02-14 Green Biomed, Inc. Cross-immunizing antigen vaccine and method for preparation thereof
KR102004693B1 (en) * 2018-01-15 2019-07-29 주식회사 티앤디바이오 Peptide specifically binding to envelope protein of zika virus and uses thereof
KR102012123B1 (en) 2018-01-29 2019-08-19 충북대학교 산학협력단 Hybridomas that produce specific antibodies that bind simultaneously to non-structural protein 1 of dengue virus and Zika virus and antibodies produced therefrom, and uses thereof
KR102008608B1 (en) 2018-01-29 2019-08-07 충북대학교 산학협력단 Hybridomas that produce specific antibodies to non-structural protein 1 of dengue virus and antibodies produced therefrom, and uses thereof
MX2020009296A (en) 2018-03-15 2020-11-13 Chugai Pharmaceutical Co Ltd Anti-dengue virus antibodies having cross-reactivity to zika virus and methods of use.
CA3094324A1 (en) 2018-03-26 2019-10-03 Clear Creek Bio, Inc. Compositions and methods for inhibiting dihydroorotate dehydrogenase
CN109320607B (en) * 2018-09-06 2021-10-08 中国人民解放军第二军医大学 Nano antibody for resisting dengue virus DE3, preparation method and application
CN111320688B (en) * 2018-12-17 2021-08-24 中国科学院天津工业生物技术研究所 Flavivirus neutralizing antibody, preparation method and application thereof
CN109929033B (en) * 2019-03-15 2020-06-02 中国人民解放军军事科学院军事医学研究院 Human antibody specifically binding to four serotype dengue viruses
WO2020210373A1 (en) * 2019-04-09 2020-10-15 Tremeau Pharmaceuticals, Inc. Treatment of viral hemorrhagic fevers with etoricoxib
US20220372079A1 (en) * 2019-06-24 2022-11-24 Jonathan R. Lai Resurfaced dengue virus and ziki virus glycoprotein e diii variants and uses thereof

Family Cites Families (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
JPS6147500A (en) 1984-08-15 1986-03-07 Res Dev Corp Of Japan Chimera monoclonal antibody and its preparation
EP0173494A3 (en) 1984-08-27 1987-11-25 The Board Of Trustees Of The Leland Stanford Junior University Chimeric receptors by dna splicing and expression
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
JPS61134325A (en) 1984-12-04 1986-06-21 Teijin Ltd Expression of hybrid antibody gene
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
WO1988007089A1 (en) 1987-03-18 1988-09-22 Medical Research Council Altered antibodies
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
IL91501A (en) 1988-09-02 1998-03-10 Dyax Corp Generation of a variegated library of mutant potential binding proteins and screening of said library for proteins with a desired binding activity
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
GB8905669D0 (en) 1989-03-13 1989-04-26 Celltech Ltd Modified antibodies
WO1991000906A1 (en) 1989-07-12 1991-01-24 Genetics Institute, Inc. Chimeric and transgenic animals capable of producing human antibodies
DE69133566T2 (en) 1990-01-12 2007-12-06 Amgen Fremont Inc. Formation of xenogenic antibodies
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
ATE185601T1 (en) 1990-07-10 1999-10-15 Cambridge Antibody Tech METHOD FOR PRODUCING SPECIFIC BONDING PAIRS
DK0814159T3 (en) 1990-08-29 2005-10-24 Genpharm Int Transgenic, non-human animals capable of forming heterologous antibodies
WO1992003917A1 (en) 1990-08-29 1992-03-19 Genpharm International Homologous recombination in mammalian cells
WO1992009690A2 (en) 1990-12-03 1992-06-11 Genentech, Inc. Enrichment method for variant proteins with altered binding properties
DE69233697T2 (en) 1991-03-01 2008-01-24 Dyax Corp., Cambridge Process for the development of binding microproteins
DK1471142T3 (en) 1991-04-10 2009-03-09 Scripps Research Inst Heterodimeric receptor libraries using phagemids
EP0519596B1 (en) 1991-05-17 2005-02-23 Merck & Co. Inc. A method for reducing the immunogenicity of antibody variable domains
DE4122599C2 (en) 1991-07-08 1993-11-11 Deutsches Krebsforsch Phagemid for screening antibodies
PT1498427E (en) 1992-08-21 2010-03-22 Univ Bruxelles Immunoglobulins devoid of light chains
EP2290108B1 (en) 2001-05-22 2014-07-23 THE GOVERNMENT OF THE UNITED STATES OF AMERICA as represented by the SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES Development of mutations useful for attenuating dengue viruses and chimeric dengue viruses
US7232888B2 (en) 2002-07-01 2007-06-19 Massachusetts Institute Of Technology Antibodies against tumor surface antigens
US7473424B2 (en) 2003-01-31 2009-01-06 The Scripps Research Institute Anti-dengue virus antibodies and compositions
WO2005056600A2 (en) 2003-12-08 2005-06-23 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Monoclonal antibodies that bind or neutralize dengue virus
EP1879921B1 (en) 2005-05-12 2011-04-27 Crucell Holland B.V. Host cell specific binding molecules capable of neutralizing viruses and uses thereof
US7943134B2 (en) 2005-08-31 2011-05-17 Academia Sinica Compositions and methods for identifying response targets and treating flavivirus infection responses
CU23586A1 (en) 2005-11-22 2010-10-30 Ct Ingenieria Genetica Biotech METHODS AND PROTEINS FOR THE PROPHLACTIC AND / OR THERAPEUTIC TREATMENT OF THE FOUR SEROTYPES OF THE DENGUE VIRUS AND OTHER FLAVIVIRUS
CU23632A1 (en) 2006-04-28 2011-02-24 Ct Ingenieria Genetica Biotech METHODS FOR THE IDENTIFICATION OF THERAPEUTIC CANDIDATES AGAINST DISEASES CAUSED BY FLAVIVIRUS AND ANTIVIRAL MOLECULES.
WO2009011941A2 (en) 2007-04-04 2009-01-22 The Government Of U.S.A., As Represented By The Secretary, Departmetnt Of Health & Human Services Monoclonal antibodies against dengue and other viruses with deletion in fc region
US20100150912A1 (en) 2007-04-11 2010-06-17 Novartis Ag Blocking interaction between pathogen factors and factor h to inhibit hemorrhagic syndromes
MX2011003588A (en) 2008-10-13 2011-10-14 Inst Research In Biomedicine Dengue virus neutralizing antibodies and uses thereof.
WO2010093335A1 (en) 2009-02-10 2010-08-19 Nanyang Technological University Antibodies for diagnosis and treatment of flaviviral infections
RU2011140498A (en) 2009-03-06 2013-04-20 Дженентек, Инк. PREPARATION ANTIBODIES
WO2011028962A1 (en) 2009-09-04 2011-03-10 Xoma Technology Ltd. Antibody coformulations
IT1395574B1 (en) 2009-09-14 2012-10-16 Guala Dispensing Spa DISTRIBUTION DEVICE
US8637035B2 (en) 2010-07-16 2014-01-28 Academia Sinica Anti-dengue virus antibodies
KR101781546B1 (en) 2010-12-14 2017-09-26 내셔널 유니버시티 오브 싱가포르 Human monoclonal antibody with specificity for dengue virus serotype 1 e protein and uses thereof
MY170725A (en) * 2011-09-09 2019-08-27 Univ Osaka Dengue-virus serotype neutralizing antibodies
US20140349321A1 (en) 2011-12-16 2014-11-27 Agency For Science, Technology And Research Binding molecules against dengue virus and uses thereof
US8920804B2 (en) 2011-12-22 2014-12-30 Inbios International, Inc. Methods and materials for the detection of dengue virus infection
EP2834265A4 (en) 2012-04-02 2015-10-14 Univ North Carolina Methods and compositions for dengue virus epitopes
US9556254B2 (en) 2012-05-14 2017-01-31 The Usa, As Represented By The Secretary, Dept. Of Health And Human Services Cross-reactive antibodies against dengue virus and uses thereof
SG11201500605TA (en) 2012-08-07 2015-02-27 Massachusetts Inst Technology Anti-dengue virus antibodies and uses thereof
WO2014110092A1 (en) 2013-01-08 2014-07-17 Humabs Biomed Sa Methods of generating robust passive and active immune responses
WO2015123362A1 (en) 2014-02-11 2015-08-20 Massachusetts Institute Of Technology Novel full spectrum anti-dengue antibody
KR102356951B1 (en) 2014-02-11 2022-01-27 비스테라, 인크. Antibody molecules to dengue virus and uses thereof
US20170274076A1 (en) 2016-03-25 2017-09-28 Visterra, Inc. Formulations of antibody molecules to dengue virus

Also Published As

Publication number Publication date
US9365639B2 (en) 2016-06-14
JP2017512209A (en) 2017-05-18
US20160251413A1 (en) 2016-09-01
AU2015217572B2 (en) 2020-10-15
ES2900749T3 (en) 2022-03-18
CN106211773A (en) 2016-12-07
IL247221B (en) 2022-01-01
CA2938590A1 (en) 2015-08-20
US20160046697A1 (en) 2016-02-18
CN113817053A (en) 2021-12-21
AU2015217572A1 (en) 2016-08-18
JP6764348B2 (en) 2020-09-30
IL247221A0 (en) 2016-09-29
CN106211773B (en) 2021-09-03
WO2015122995A1 (en) 2015-08-20
EP3105249A1 (en) 2016-12-21
US20190153074A1 (en) 2019-05-23
US20220177553A1 (en) 2022-06-09
KR20160117608A (en) 2016-10-10
EP3105249B1 (en) 2021-09-15
US11059883B2 (en) 2021-07-13
US20150225474A1 (en) 2015-08-13
US10155806B2 (en) 2018-12-18
US9212217B2 (en) 2015-12-15
EP4047015A1 (en) 2022-08-24
KR102356951B1 (en) 2022-01-27
MX2016010360A (en) 2016-11-30
CA2938590C (en) 2023-10-17
CA3212977A1 (en) 2015-08-20

Similar Documents

Publication Publication Date Title
SG11201606624WA (en) Antibody moleules to dengue virus and uses thereof
HK1255067A1 (en) Anti-c10orf54 antibodies and uses thereof
HK1243440A1 (en) Anti-interleukin-33 antibodies and uses thereof
HK1254337A1 (en) Antibody molecules to april and uses thereof
IL251563A0 (en) Antibody molecules to pd-l1 and uses thereof
ZA201605894B (en) Anti-egfrviii antibodies and uses thereof
GB201403875D0 (en) Novel antibodies and uses thereof
GB201413913D0 (en) Novel antibodies and uses thereof
IL282201B (en) Anti-tenascin c antibodies and uses thereof
ZA201701663B (en) Anti-il-25 antibodies and uses thereof
SG11201705748SA (en) Anti-glycoprotein antibodies and uses thereof
TH1501003909A (en) Antibodies to PDGFR-beta and their uses